Neflamapimod is under clinical development by EIP Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Neflamapimod’s likelihood of approval (LoA) and phase transition for Lewy Body Dementia took place on 10 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Neflamapimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Neflamapimod overview

Neflamapimod (VX-745) is under development for the treatment of Alzheimer’s disease, Lewy body dementia, cognitive defects in Huntington disease and acute ischemic stroke. The drug candidate is administered through oral route as a hard gelatin capsule. It acts by targeting alpha isoform of the protein enzyme p38 mitogen-activated protein kinase (p38 MAPK alpha). It was also under development for the treatment of rheumatoid arthritis.

EIP Pharma overview

EIP Pharma Inc (EIP Pharma) is a biopharmaceutical company that discovers, develops and commercializes drugs for the treatment of alzheimer, dementia and neurodegenerative diseases. The company is headquartered in Boston, Massachusetts, the US.

Quick View Neflamapimod LOA Data

Report Segments
  • Innovator
Drug Name
  • Neflamapimod
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Immunology
Key Developers
  • Sponsor Company: EIP Pharma
  • Originator: Vertex Pharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.